Atria Investments Inc Has $164,000 Stake in Veru Inc. $VERU

Atria Investments Inc grew its holdings in shares of Veru Inc. (NASDAQ:VERU) by 11.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 282,281 shares of the company’s stock after purchasing an additional 29,025 shares during the period. Atria Investments Inc owned about 0.19% of Veru worth $164,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Choreo LLC boosted its stake in shares of Veru by 67.4% in the first quarter. Choreo LLC now owns 669,277 shares of the company’s stock valued at $328,000 after buying an additional 269,500 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Veru by 19.3% during the 1st quarter. Bank of New York Mellon Corp now owns 377,043 shares of the company’s stock valued at $185,000 after acquiring an additional 61,002 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Veru in the second quarter valued at about $90,000. MPM Bioimpact LLC grew its stake in Veru by 53.8% during the first quarter. MPM Bioimpact LLC now owns 6,592,727 shares of the company’s stock worth $3,231,000 after buying an additional 2,307,362 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Veru by 21.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 375,291 shares of the company’s stock worth $184,000 after acquiring an additional 65,045 shares during the period. 47.16% of the stock is owned by institutional investors.

Veru Stock Performance

VERU stock opened at $2.54 on Friday. The company has a market capitalization of $37.23 million, a P/E ratio of -1.15 and a beta of -0.80. The company has a fifty day moving average price of $3.54 and a 200-day moving average price of $4.56. Veru Inc. has a 52-week low of $2.42 and a 52-week high of $14.20.

Veru (NASDAQ:VERU) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.05. As a group, sell-side analysts forecast that Veru Inc. will post -0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Raymond James Financial reduced their target price on Veru from $30.00 to $20.00 and set an “outperform” rating on the stock in a report on Wednesday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Veru in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $25.00.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.